T3D Therapeutics

OverviewSuggest Edit

T3D Therapeutics is a clinical-stage drug development company. It is engaged in the development of remedial therapeutics for Alzheimer's disease and other CNS disorders.

TypePrivate
Founded2013
HQNC, US
Websitet3dtherapeutics.com

Latest Updates

Cybersecurity ratingAMore

Key People/Management at T3D Therapeutics

John Didsbury

John Didsbury

President & CEO, Chairman of the Board
Warren Strittmatter

Warren Strittmatter

Chief Medical Officer
Stan Chamberlain

Stan Chamberlain

Chief Scientific Officer
Hoda Gabriel

Hoda Gabriel

Vice President Clinical Development
Jessica Stanek

Jessica Stanek

Associate Director Clinical Development
Blake Swearingen

Blake Swearingen

Director, Clinical Development
Show more

T3D Therapeutics Office Locations

T3D Therapeutics has an office in
Show all (1)

T3D Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2013

T3D Therapeutics total Funding

$34.3 m

T3D Therapeutics latest funding size

$15 m

Time since last funding

a year ago

T3D Therapeutics investors

T3D Therapeutics's latest funding round in November 2019 was reported to be $15 m. In total, T3D Therapeutics has raised $34.3 m
Show all financial metrics

T3D Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

T3D Therapeutics Online and Social Media Presence

Embed Graph

T3D Therapeutics News and Updates

T3D Therapeutics Receives a Research Award from the Alzheimer's Association Part the Cloud-Gates Partnership Grant Program

RESEARCH TRIANGLE PARK, N.C., Aug. 27, 2020 /PRNewswire/ -- T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer's disease (AD), announced today that it has received a $740,000 grant from the...

T3D Therapeutics Blogs

T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer’s Disease

RESEARCH TRIANGLE PARK, N.C., April 20, 2021 / T3D Therapeutics, Inc. (“T3D”), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced today the initiation of dosing in a Phase 2 clinical study of ne…

T3D Therapeutics Frequently Asked Questions

  • When was T3D Therapeutics founded?

    T3D Therapeutics was founded in 2013.

  • Who are T3D Therapeutics key executives?

    T3D Therapeutics's key executives are John Didsbury, Warren Strittmatter and Stan Chamberlain.

  • Who are T3D Therapeutics competitors?

    Competitors of T3D Therapeutics include Dabur, Odan Laboratories and BioVectra.

  • Where are T3D Therapeutics offices?

    T3D Therapeutics has an office in.

  • How many offices does T3D Therapeutics have?

    T3D Therapeutics has 1 office.